23:31 , Dec 12, 2018 |  BC Extra  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
20:56 , Nov 29, 2018 |  BC Innovations  |  Translation in Brief

Predicting respiratory response

A University of California San Francisco team has described a gene signature that identifies a subgroup of chronic obstructive pulmonary disease (COPD) patients who could benefit from IL-17A inhibitors if they don’t respond to corticosteroids....
18:48 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
17:55 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture, mouse, rat and dog studies identified a RORγT inverse agonist that could help treat inflammation. Chemical synthesis and screening of a subset of Pfizer Inc.’s small compound library in a HEK-cell...
17:33 , Jul 20, 2018 |  BC Week In Review  |  Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos...
20:37 , Jul 19, 2018 |  BC Extra  |  Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos...
18:21 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Lilly's Taltz meets in Phase III for TNF inhibitor-experienced ankylosing spondylitis

Eli Lilly and Co. (NYSE:LLY) said Taltz ixekizumab met the primary endpoint of a greater proportion of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at week 16 vs. placebo in the...
19:42 , May 18, 2018 |  BC Week In Review  |  Clinical News

Novartis to start head-to-head trial of Cosentyx and Tremfya

Novartis AG (NYSE:NVS; SIX:NOVN) plans to begin the head-to-head Phase IIa ARROW trial to compare Cosentyx secukinumab to Tremfya guselkumab for 16 weeks in 40 patients with Stelara ustekinumab-resistant plaque psoriasis. The pharma expects to...
17:43 , May 11, 2018 |  BC Week In Review  |  Clinical News

Lilly’s Taltz meets in Phase III for ankylosing spondylitis

In February, Eli Lilly and Co. (NYSE:LLY) reported top-line data from the Phase III COAST-V trial to treat axial spondyloarthritis showing that subcutaneous Taltz ixekizumab met the primary endpoint of a greater proportion of patients...